1
|
Romo-García MF, Nava-Ramírez HS, Zapata-Zúñiga M, Macías-Segura N, Santiago-Algarra D, Castillo-Ortiz JD, Bastián Y, Ramos-Remus C, Enciso-Moreno JA, Castañeda-Delgado JE. Evaluation of SUMO1 and POU2AF1 in whole blood from rheumatoid arthritis patients and at risk relatives. Int J Immunogenet 2019; 46:59-66. [PMID: 30681271 DOI: 10.1111/iji.12414] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2018] [Revised: 08/21/2018] [Accepted: 11/25/2018] [Indexed: 12/27/2022]
Abstract
Rheumatoid arthritis (RA) is a systemic autoimmune disorder characterized by chronic and symmetrical inflammation of synovial tissue with subsequent joint destruction. SUMO1 is an important regulator of apoptosis through non-canonical mechanism in synovial fibroblasts, and POU2AF1 is a known B-cell transcriptional co-activator. The specific objective of this study was to measure the expression of SUMO1 and POU2AF1 on first-degree relatives of patients with RA and also in the preclinical and clinical stages of RA and describe their possible role in RA physiopathology. Blood samples were collected from ACPA+, ACPA-, early and established RA subjects recruited. ACPAs and CarP autoantibodies were determined by ELISA Eurodiagnostica CCplus kit according to previously described protocols. RNA was isolated from blood samples; the purity as integrity was determined. Gene expression analysis was made by RT-qPCR using specific primers for SUMO1 and POU2AF1 mRNAs; relative expression was determined according to the 2-ΔΔct method procedure. Significant differences in the expression of both, SUMO1 and POU2AF1 were identified when comparing arthritis versus healthy or ACPA+ individuals, suggesting that the down regulation of such genes starts after the onset of symptoms in RA patients. Also, a significant correlation was identified for POU2AF1 and disease progression whit a downward trend for those with established RA. The implications of such gene down regulation are discussed in the context of RA physiopathology.
Collapse
Affiliation(s)
- Maria Fernanda Romo-García
- Unidad de Investigación Biomédica de Zacatecas, IMSS, Zacatecas, México.,Facultad de Medicina, Departamento de Inmunología, Universidad Autónoma de San Luis Potosí, San Luis Potosí, México
| | | | - Martin Zapata-Zúñiga
- Hospital Rural No 51 IMSS Bienestar, Villanueva, Zacatecas, México.,Facultad de Medicina y Ciencias de la Salud, Universidad Autónoma de Zacatecas, Zacatecas, México
| | - Noe Macías-Segura
- Unidad de Investigación Biomédica de Zacatecas, IMSS, Zacatecas, México.,Departamento de Fisiología, Centro de Ciencias Básicas, Universidad Autónoma de Aguascalientes, Aguascalientes, México
| | | | | | - Yadira Bastián
- Cátedras-CONACyT-Unidad de Investigación Biomédica de Zacatecas-IMSS, Zacatecas, México
| | - Cesar Ramos-Remus
- Unidad de Investigación en Enfermedades Crónico-Degenerativas, Guadalajara, México.,Universidad Autónoma de Guadalajara, Guadalajara, México
| | | | | |
Collapse
|
2
|
Piantoni S, Colombo E, Tincani A, Airò P, Scarsi M. Predictive factors of abatacept therapy discontinuation in patients with rheumatoid arthritis. Clin Rheumatol 2016; 35:1065-9. [PMID: 26809797 DOI: 10.1007/s10067-016-3185-1] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2015] [Revised: 01/11/2016] [Accepted: 01/14/2016] [Indexed: 11/24/2022]
Abstract
The aim of this paper was to look for predictors of abatacept (ABA) therapy discontinuation in patients with rheumatoid arthritis (RA). Seventy-one RA patients treated with ABA were followed up. Demographical, clinical, and laboratory parameters of the patients, including peripheral blood T and B cell populations, different rheumatoid factor and anti-cyclic citrullinated peptide autoantibodies isotypes, and serum free light chains were evaluated. Comparing patients who discontinued ABA with those still in therapy we observed: a higher proportion of smokers (51.9 vs 25.6 %; p = 0.03); a non significant lower proportion of anti-cyclic citrullinated peptide positivity (76 vs 89.5 %; p = 0.13); a lower proportion of terminally differentiated effector memory cells (TDEM) among total CD8+ T lymphocytes at baseline (22.0 % (7.8-39.2) vs 38.7 % (20.7-55.9); p = 0.002). Logistic multivariate analysis showed that only the proportion of CD8+TDEM T cells was an independent predictive factor of therapy discontinuation (OR (95 % IC) = 6.2 (1.2 to 30.8); p = 0.026). Receiver-operating characteristic analysis showed a significant performance of this biomarker for prediction of therapy discontinuation (using a cut-off of 30.6 %: AUC: 0.760 ± 0.07; p = 0.002). Patients with a low proportion of CD8+TDEM at baseline had a higher probability of discontinuing the treatment during time (log-rank test: p < 0.01). T cell characterization for identification of TDEM CD8+ T cells might be a useful test to predict discontinuation of ABA therapy.
Collapse
Affiliation(s)
- Silvia Piantoni
- Rheumatology and Clinical Immunology Unit, Spedali Civili of Brescia, P.le Spedali Civili 1, 25123, Brescia, Italy. .,Rheumatology Chair, University of Pavia, Pavia, Italy. .,Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
| | - Enrico Colombo
- Rheumatology and Clinical Immunology Unit, Spedali Civili of Brescia, P.le Spedali Civili 1, 25123, Brescia, Italy
| | - Angela Tincani
- Rheumatology and Clinical Immunology Unit, Spedali Civili of Brescia, P.le Spedali Civili 1, 25123, Brescia, Italy.,Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy
| | - Paolo Airò
- Rheumatology and Clinical Immunology Unit, Spedali Civili of Brescia, P.le Spedali Civili 1, 25123, Brescia, Italy
| | - Mirko Scarsi
- Rheumatology and Clinical Immunology Unit, Spedali Civili of Brescia, P.le Spedali Civili 1, 25123, Brescia, Italy.,Internal Medicine Unit, Esine-Vallecamonica Hospital, ASL Vallecamonica-Sebino, Esine, Italy
| |
Collapse
|